Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology
Open accessThe DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions. Its prevalence, long-term evolution in adults and neuropathology are not well known. We identified a series of 22 adult patients, including three adult post-mortem cases with Dravet syndrome. For all patients, we reviewed the clinical history, seizure types and frequency, antiepileptic drugs, cognitive, social and functional outcome and results of investigations. A systematic neuropathology study was performed, with post-mortem material from three adult cases with Dravet syndrome, in comparison with controls and a range of relevant paediatric tissue. Twenty-two adults with Dravet syndrome, 10 female, were included, median age 39 years (range 20-66). SCN1A structural variation was found in 60% of the adult Dravet patients tested, including one post-mortem case with DNA extracted from brain tissue. Novel mutations were described for 11 adult patients; one patient had three SCN1A mutations. Features of Dravet syndrome in adulthood include multiple seizure types despite polytherapy, and age-dependent evolution in seizure semiology and electroencephalographic pattern. Fever sensitivity persisted through adulthood in 11 cases. Neurological decline occurred in adulthood with cognitive and motor deterioration. Dysphagia may develop in or after the fourth decade of life, leading to significant morbidity, or death. The correct diagnosis at an older age made an impact at several levels. Treatment changes improved seizure control even after years of drug resistance in all three cases with sufficient follow-up after drug changes were instituted; better control led to significant improvement in cognitive performance and quality of life in adulthood in two cases. There was no histopathological hallmark feature of Dravet syndrome in this series. Strikingly, there was remarkable preservation of neurons and interneurons in the neocortex and hippocampi of Dravet adult post-mortem cases. Our study provides evidence that Dravet syndrome is at least in part an epileptic encephalopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, cessation of specific sodium channel blockers, which are contraindicated in Dravet syndrome, leads to improved seizure control and developmental gains in children and adults with Dravet syndrome 232 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [232]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berg, A. T., Berkovic, S. F., Brodie, M. J., Buchhalter, J., Cross, J. H., Van Emde Boas, W., Engel, J., French, J., Glauser, T. A., Mathern, G. W., et al. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02522.x · Cited by 4,363 · cited 2×
“…Against Epilepsy classification (Engel et al., 2001) and a syndrome carrying higher risk of epileptic encephalopathy in the recent reorganization (Berg et al., 2010), but controversy exists as to whether the seizures and interictal discharges themselves are responsible for the cognitive…”
BackgroundSelf-citationEngel, J. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.10401.x · Cited by 2,251
Blümcke, I., Thom, M., Aronica, E., Armstrong, D. D., Vinters, H. V., Palmini, A., Jacques, T. S., Avanzini, G., Barkovich, A. J., Battaglia, G., et al. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02777.x · Cited by 1,743
Self-citationDe Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy
Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., & De Jonghe, P. (2001) · The American Journal of Human Genetics · doi:10.1086/320609 · Cited by 1,292
Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006) · Nature Neuroscience · doi:10.1038/nn1754 · Cited by 1,173 · cited 7×
“1) in Purkinje cells, leading to abnormal sodium flux, may contribute to ataxia observed in animal models (Yu et al., 2006).”
BackgroundResultInfluentialBrain Inflammation in Epilepsy: Experimental and Clinical Evidence
Vezzani, A., & Granata, T. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00298.x · Cited by 1,036 · cited 1×
“Immune-inflammatory mediators have received attention in epileptogenesis, febrile seizures and some chronic epilepsies (Vezzani and Granata, 2005; Ravizza et al., 2008; Vezzani et al., 2008).”
Background(2005) · Cited by 944
Ogiwara, I., Miyamoto, H., Morita, N., Atapour, N., Mazaki, E., Inoue, I., Takeuchi, T., Itohara, S., Yanagawa, Y., Obata, K., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5270-06.2007 · Cited by 879 · cited 4×
“Sodium currents are significantly reduced in inhibitory interneurons in both hippocampus and cortex, but less so in hippocampal pyramidal cells (Yu et al., 2006; Ogiwara et al., 2007).”
BackgroundResultInfluentialRavizza, T., Gagliardi, B., Noé, F., Boer, K., Aronica, E., & Vezzani, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.08.012 · Cited by 699 · cited 1×
“Immune-inflammatory mediators have received attention in epileptogenesis, febrile seizures and some chronic epilepsies (Vezzani and Granata, 2005; Ravizza et al., 2008; Vezzani et al., 2008).”
Background
Research works printed but not linked: 3
- 2009, Journal of Medical Genetics, 46, 183, 10.1136/jmg.2008.062323 · DOI · Paper page
- 2009, Journal of Medical Genetics, 46, 671, 10.1136/jmg.2008.060897 · DOI · Paper page
- 2010, Journal of Biological Chemistry, 285, 9823, 10.1074/jbc.m109.078568 · DOI · Paper page
Cited by
Diagnostic exome sequencing in persons with severe intellectual disability
de Ligt, J., Willemsen, M. H., van Bon, B. W. M., Kleefstra, T., Yntema, H. G., Kroes, T., Vulto-van Silfhout, A. T., Koolen, D. A., de Vries, P., Gilissen, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206524 · Cited by 1,546
The genetic landscape of the epileptic encephalopathies of infancy and childhood
McTague, A., Howell, K. B., Cross, J. H., Kurian, M. A., & Scheffer, I. E. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00250-1 · Cited by 604
Self-citationLagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J. H., Guerrini, R., Talwar, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32500-0 · Cited by 384
Self-citationPrognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
Brunklaus, A., Ellis, R., Reavey, E., Forbes, G. H., & Zuberi, S. M. (2012) · Brain · doi:10.1093/brain/aws151 · Cited by 366
“However, it is not clear whether the developmental regression is primarily caused by the genetic change itself as a consequence of the epileptic encephalopathy, or by both (Catarino et al., 2011).”
BackgroundSelf-citationCooper, M. S., Mcintosh, A., Crompton, D. E., McMahon, J. M., Schneider, A., Farrell, K., Ganesan, V., Gill, D., Kivity, S., Lerman-Sagie, T., et al. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.10.006 · Cited by 316
Self-citationWirrell, E. C., Laux, L., Donner, E., Jette, N., Knupp, K., Meskis, M. A., Miller, I., Sullivan, J., Welborn, M., & Berg, A. T. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.01.025 · Cited by 283
Sudden unexpected death in a mouse model of Dravet syndrome
Kalume, F., Westenbroek, R. E., Cheah, C. S., Yu, F. H., Oakley, J. C., Scheuer, T., & Catterall, W. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66220 · Cited by 282
“Similarly, as in DS mice, most SUDEP cases in patients with DS and other types of epilepsy occur in sleep (9, 12, 47, 48).”
BackgroundLong‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Devinsky, O., Nabbout, R., Miller, I., Laux, L., Zolnowska, M., Wright, S., & Roberts, C. (2019) · Epilepsia · doi:10.1111/epi.14628 · Cited by 271
Colasante, G., Lignani, G., Brusco, S., Di Berardino, C., Carpenter, J., Giannelli, S., Valassina, N., Bido, S., Ricci, R., Castoldi, V., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.018 · Cited by 231
Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy
Nabbout, R., Chemaly, N., Chipaux, M., Barcia, G., Bouis, C., Dubouch, C., Leunen, D., Jambaqué, I., Dulac, O., Dellatolas, G., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-176 · Cited by 197
“Developmental delay in DS is usually considered as a result of severe epilepsy, and the term “epileptic encephalopathy” therefore often applied [5-7].”
BackgroundEpilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A
Kasperavičiūtė, D., Catarino, C. B., Matarin, M., Leu, C., Novy, J., Tostevin, A., Leal, B., Hessel, E. V. S., Hallmann, K., Hildebrand, M. S., et al. (2013) · Brain · doi:10.1093/brain/awt233 · Cited by 198
“…association is with a syndrome involving hippocampal damage, whereas typically no hippocampal damage is observed in patients with Dravet syndrome caused by deleterious changes affecting SCN1A (Catarino et al., 2011), suggesting that SCN1A might influence epileptogenesis through various mechanisms.”
BackgroundInfluentialSelf-citationMortality in Dravet syndrome: A review
Shmuely, S., Sisodiya, S. M., Gunning, W. B., Sander, J. W., & Thijs, R. D. (2016) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.09.007 · Cited by 184
“Adults may have thus missed out on a diagnosis [52,53].”
Self-citationScheffer, I. E., & Liao, J. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2019.12.023 · Cited by 180
Self-citationFrom genotype to phenotype in Dravet disease
Gataullina, S., & Dulac, O. (2017) · Seizure · doi:10.1016/j.seizure.2016.10.014 · Cited by 177
Precision medicine and therapies of the future
Sisodiya, S. M. (2020) · Epilepsia · doi:10.1111/epi.16539 · Cited by 185
Self-citationParrini, E., Marini, C., Mei, D., Galuppi, A., Cellini, E., Pucatti, D., Chiti, L., Rutigliano, D., Bianchini, C., Virdò, S., et al. (2017) · Human Mutation · doi:10.1002/humu.23149 · Cited by 163
Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies
Guery, D., & Rheims, S. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s256699 · Cited by 185
“For instance, drug-resistance is virtually observed in all patients with Dravet Syndrome.27,28 However, SCN1A mutations, which are associated with Dravet syndrome, can also be associated with Genetic Epilepsy with Febrile Seizures Plus (GEFS+),29 resulting in potential implications for treatment specially to avoid pse…”
BackgroundThom, M., Liu, J. Y. W., Thompson, P., Phadke, R., Narkiewicz, M., Martinian, L., Marsdon, D., Koepp, M., Caboclo, L., Catarino, C. B., et al. (2011) · Brain · doi:10.1093/brain/awr209 · Cited by 167
“This is highlighted in the present series in three patients with Dravet syndrome with cognitive decline in which we have reported an absence of neuropathological or degenerative changes (Catarino et al., 2011).”
BackgroundSelf-citationde Lange, I. M., Gunning, B., Sonsma, A. C. M., van Gemert, L., van Kempen, M., Verbeek, N. E., Nicolai, J., Knoers, N. V. A. M., Koeleman, B. P. C., & Brilstra, E. H. (2018) · Epilepsia · doi:10.1111/epi.14191 · Cited by 161
“Interpolated IQ/DQ score after 5 years of disease, mean (range) 62 (19-100) 81 (44-100) 55 (20-96)”
Dravet syndrome—From epileptic encephalopathy to channelopathy
Brunklaus, A., & Zuberi, S. M. (2014) · Epilepsia · doi:10.1111/epi.12652 · Cited by 161
Self-citationDevelopmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
“For example, cessation of specific sodium channel blockers, which are contraindicated in Dravet syndrome, leads to improved seizure control and developmental gains in children and adults with Dravet syndrome 232 .”
Self-citationEpilepsy and autism: Is there a special relationship?
Berg, A. T., & Plioplys, S. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.01.015 · Cited by 144
“A high prevalence of autistic features although not necessarily classical autism per se is also reported in association with Dravet syndrome [9, 75, 76] and in Epilepsy in Females with Mental Retardation [10].”
BackgroundClinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations
Cetica, V., Chiari, S., Mei, D., Parrini, E., Grisotto, L., Marini, C., Pucatti, D., Ferrari, A., Sicca, F., Specchio, N., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003716 · Cited by 135
“…the causative gene for Dravet syndrome and that some authors have subsequently described mutated patients with Dravet syndrome and seizure onset beyond the first year of life, 7 – 9 we did not firmly predefine age at first seizure as a cutoff time for diagnosis but relied on the clinical severity.”
MethodTau reduction prevents disease in a mouse model of Dravet syndrome
Gheyara, A. L., Ponnusamy, R., Djukic, B., Craft, R. J., Ho, K., Guo, W., Finucane, M. M., Sanchez, P. E., & Mucke, L. (2014) · Annals of Neurology · doi:10.1002/ana.24230 · Cited by 138
Sodium channelopathies of skeletal muscle and brain
Mantegazza, M., Cestèle, S., & Catterall, W. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00025.2020 · Cited by 133
Ion Channel Functions in Early Brain Development
Smith, R. S., & Walsh, C. A. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2019.12.004 · Cited by 132
“Of these NaV diseases, the most extensively studied is Dravet syndrome (SCN1A), and most pathogenic mutations in this gene result in NaV LOF pathophysiology and are accompanied by intractable epilepsy, but without a detectable MCD (Figure 3) [50].”
BackgroundDravet Syndrome: Diagnosis and Long-Term Course
Connolly, M. B. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2016.243 · Cited by 142
“In another report of 31 patients, only 1 lived independently, 7 had no language and 9 spoke only a few words.42 Catarino et al.43 described the long-term follow-up in 22 adults followed to Volume 43, No.”
BackgroundNot all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype
Sadleir, L. G., Mountier, E. I., Gill, D., Davis, S., Joshi, C., DeVile, C., Kurian, M. A., Study, F. T. D., Mandelstam, S., Wirrell, E., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004331 · Cited by 131
Self-citationChannelopathy pathogenesis in autism spectrum disorders
Schmunk, G., & Gargus, J. J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00222 · Cited by 124
“…capable of causing seizure syndromes and seizures are frequently comorbid with ASD, the question arises whether seizure activity causes the impairments observed in ASD (Catarino et al., 2011), or if the ion channel dysfunction itself, independent of seizures, contributes to the ASD pathophysiology.”
BackgroundDefining Dravet syndrome: An essential pre‐requisite for precision medicine trials
Li, W., Schneider, A. L., & Scheffer, I. E. (2021) · Epilepsia · doi:10.1111/epi.17015 · Cited by 123
Self-citationCurrent practice in diagnostic genetic testing of the epilepsies
Krey, I., Platzer, K., Esterhuizen, A. I., Berkovic, S. F., Helbig, I., Hildebrand, M. S., Lerche, H., Lowenstein, D. H., Møller, R. S., Poduri, A., et al. (2022) · Epileptic Disorders · doi:10.1684/epd.2022.1448 · Cited by 127
Self-citationDravet syndrome: Treatment options and management of prolonged seizures
Cross, J. H., Caraballo, R. H., Nabbout, R., Vigevano, F., Guerrini, R., & Lagae, L. (2019) · Epilepsia · doi:10.1111/epi.16334 · Cited by 105
Self-citationThe ventrolateral medulla and medullary raphe in sudden unexpected death in epilepsy
Patodia, S., Somani, A., O’Hare, M., Venkateswaran, R., Liu, J. Y. W., Michalak, Z., Ellis, M. J., Scheffer, I. E., Diehl, B., Sisodiya, S. M., et al. (2018) · Brain · doi:10.1093/brain/awy078 · Cited by 111
“…probable or possible SUDEP (incomplete autopsy examination or competing cause of death identified) (Nashef et al., 2012); (ii) Seven cases with Dravet syndrome obtained from ESBTB and the University of Melbourne Australia [as previously reported (Catarino et al., 2011), between 1992 and 2010].”
MethodSelf-citationA prospective open‐label trial of a CBD / THC cannabis oil in dravet syndrome
McCoy, B., Wang, L., Zak, M., Al‐Mehmadi, S., Kabir, N., Alhadid, K., McDonald, K. P., Zhang, G., Sharma, R. K., Whitney, R., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.621 · Cited by 143
Co‐occurring malformations of cortical development and SCN 1A gene mutations
Barba, C., Parrini, E., Coras, R., Galuppi, A., Craiu, D., Kluger, G., Parmeggiani, A., Pieper, T., Schmitt‐Mechelke, T., Striano, P., et al. (2014) · Epilepsia · doi:10.1111/epi.12658 · Cited by 98
Focal Scn1a knockdown induces cognitive impairment without seizures
Bender, A. C., Natola, H., Ndong, C., Holmes, G. L., Scott, R. C., & Lenck-Santini, P.-P. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.12.021 · Cited by 91
Delahaye-Duriez, A., Srivastava, P., Shkura, K., Langley, S. R., Laaniste, L., Moreno-Moral, A., Danis, B., Mazzuferi, M., Foerch, P., Gazina, E. V., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1097-7 · Cited by 86
“However, in Dravet disease, despite evidence for interneuron dysfunction [78], neuropathological analyses have shown a striking preservation of interneurons and neurons despite decades of poorly controlled epilepsy [79].”
BackgroundThe SCN1A gene variants and epileptic encephalopathies
Parihar, R., & Ganesh, S. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.77 · Cited by 89
The Problem of Rarity: Estimation of Prevalence in Rare Disease
Auvin, S., Irwin, J., Abi-Aad, P., & Battersby, A. (2018) · Value in Health · doi:10.1016/j.jval.2018.03.002 · Cited by 94
Diagnostic Approach to Genetic Causes of Early-Onset Epileptic Encephalopathy
Gürsoy, S., & Erçal, D. (2016) · Journal of Child Neurology · doi:10.1177/0883073815599262 · Cited by 84
“These fatalities are observed at any age, but the majority of them takes place in young adults under polytherapy and during sleep.(39,40) The mutations in some ion channel genes (ie, SCN1A, etc) that lead to epilepsy may also constitute a risk factor for sudden unexpected death by causing cardiac or respiratory dysfun…”
BackgroundLong‐term course of D ravet syndrome: A study from an epilepsy center in J apan
Takayama, R., Fujiwara, T., Shigematsu, H., Imai, K., Takahashi, Y., Yamakawa, K., & Inoue, Y. (2014) · Epilepsia · doi:10.1111/epi.12532 · Cited by 93
Utility of genetic testing for therapeutic decision‐making in adults with epilepsy
Johannesen, K. M., Nikanorova, N., Marjanović, D., Pavbro, A., Larsen, L. H. G., Rubboli, G., & Møller, R. S. (2020) · Epilepsia · doi:10.1111/epi.16533 · Cited by 90
Sullivan, J. E., Benitez, A., Roth, J., Andrews, J. S., Shah, D., Butcher, E., Jones, A., & Cross, J. H. (2024) · Epilepsia · doi:10.1111/epi.17866 · Cited by 86
“Twelve studies 18,39,43,49,50,54,55,58,59,65,90,103 were based in Europe, specifically Finland, France, Germany, Sweden, and the UK.”
Self-citationValassina, N., Brusco, S., Salamone, A., Serra, L., Luoni, M., Giannelli, S. G., Bido, S., Massimino, L., Ungaro, F., Mazzara, P. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27837-w · Cited by 85
Pharmacotherapy for Dravet Syndrome
Wallace, A. D., Wirrell, E. C., & Kenney‐Jung, D. L. (2016) · Pediatric Drugs · doi:10.1007/s40272-016-0171-7 · Cited by 88
“Motor impairment associated with DS can be progressive [88].”
Backgroundvan Harssel, J. J. T., Weckhuysen, S., van Kempen, M. J. A., Hardies, K., Verbeek, N. E., de Kovel, C. G. F., Gunning, W. B., van Daalen, E., de Jonge, M. V., Jansen, A., et al. (2013) · Neurogenetics · doi:10.1007/s10048-013-0353-1 · Cited by 83
“Most patients with Dravet syndrome carry a de novo mutation in the SCN1A gene [23] and have refractory seizures, (severe) ID and poor outcome [24–27].”
BackgroundSCN1A testing for epilepsy: Application in clinical practice
Hirose, S., Scheffer, I. E., Marini, C., Jonghe, P. D., Andermann, E., Goldman, A. M., Kauffman, M., Tan, N. C., Lowenstein, D. H., Sisodiya, S. M., et al. (2013) · Epilepsia · doi:10.1111/epi.12168 · Cited by 82
“Furthermore, recent evidence suggests that optimization of treatment even in later adult life may improve cognition (Catarino et al., 2011).”
BackgroundSelf-citationThe clinical, economic, and humanistic burden of Dravet syndrome – A systematic literature review
Sullivan, J. E., Deighton, A. M., Vila, M. C., Szabo, S. M., Maru, B. S., Gofshteyn, J. S., James, E. S., Rico, S., & Zuberi, S. M. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108661 · Cited by 80
“Table 3), with a mean age at onset ranging from 5 to 9 months [67,68].”
BackgroundInfluentialSelf-citationThe lifelong course of chronic epilepsy: the Chalfont experience
Nový, J., Belluzzo, M., Caboclo, L. O. S. F., Catarino, C. B., Yogarajah, M., Martinian, L., Peacock, J. L., Bell, G. S., Koepp, M. J., Thom, M., et al. (2013) · Brain · doi:10.1093/brain/awt117 · Cited by 75
“We also integrated pathological data from previous studies [for hippocampal sclerosis (Thom et al., 2009), and Dravet syndrome (Catarino et al., 2011)] and used the same unified subject numbering system, allowing correlation of different aspects across publications (Thom et al., 2005, 2012; Liu et…”
MethodSelf-citationScheffer, I. E., French, J. A., Valente, K. D. R., Auvin, S., Cross, J. H., & Specchio, N. (2025) · Epilepsia · doi:10.1111/epi.18265 · Cited by 72
“20 Novel therapies should aim to address both seizure and non-seizure outcomes, including all morbidities whenever possible.”
Self-citationTreatment Strategies for Dravet Syndrome
Knupp, K. G., & Wirrell, E. C. (2018) · CNS Drugs · doi:10.1007/s40263-018-0511-y · Cited by 71
Lamotrigine can be beneficial in patients with Dravet syndrome
Dalic, L., Mullen, S. A., Roulet Perez, E., & Scheffer, I. (2015) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12593 · Cited by 64
“Fever is a common seizure trigger even into adult life.(2) Mutations of SCN1A, which encodes the a1 subunit of the neuronal voltage-gated sodium channel, occur in more than 80% of patients with Dravet syndrome.”
BackgroundSelf-citationSudden unexpected death in Dravet syndrome: Respiratory and other physiological dysfunctions
Kalume, F. (2013) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2013.06.026 · Cited by 62
“under polytherapy and during sleep (Catarino et al., 2011; Genton et al., 2011).”
Guerrini, R., Marini, C., & Mantegazza, M. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0267-0 · Cited by 63
“Magnetic resonance imaging is either normal or shows nonspecific features [13, 14].”
BackgroundStrzelczyk, A., Schubert‐Bast, S., Reese, J. P., Rosenow, F., Stephani, U., & Boor, R. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.03.014 · Cited by 62
Dravet syndrome: New potential genetic modifiers, imaging abnormalities, and ictal findings
Gaily, E., Anttonen, A., Valanne, L., Liukkonen, E., Träskelin, A., Polvi, A., Lommi, M., Muona, M., Eriksson, K., & Lehesjoki, A. (2013) · Epilepsia · doi:10.1111/epi.12256 · Cited by 60
“Hippocampal sclerosis was also rare in two recent outcome studies (Akiyama et al., 2010; Ragona et al., 2010) and in patients who were imaged in adulthood (Catarino et al., 2011).”
BackgroundResultInfluentialEpileptic encephalopathy: Use and misuse of a clinically and conceptually important concept
Howell, K. B., Harvey, A. S., & Archer, J. S. (2016) · Epilepsia · doi:10.1111/epi.13306 · Cited by 62
Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
Chiron, C., Hélias, M., Kamińska, A., Laroche, C., de Toffol, B., Dulac, O., Nabbout, R., & Gourfinkel‐An, I. (2018) · Epilepsia · doi:10.1111/epi.14536 · Cited by 58
“Two cases of motor and intellectual improvement were even reported after initiating STP and optimizing comedication at >40 years of age.(9) Optimization consisted in particular in withdrawing drugs reported as aggravating in pediatric patients with DS, such as sodium channel blockers, vigabatrin, and high doses of phe…”
BackgroundDravet syndrome: The main issues
Guerrini, R. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.04.006 · Cited by 59
Genetics of Epilepsy in Clinical Practice
Berkovic, S. F. (2015) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7511-15.4.192 · Cited by 57
Successful treatment of adult Dravet syndrome patients with cenobamate
Makridis, K. L., Friedo, A., Kellinghaus, C., Losch, F., Schmitz, B., Boßelmann, C. M., & Kaindl, A. M. (2022) · Epilepsia · doi:10.1111/epi.17427 · Cited by 54
Skjei, K. L., Church, E. W., Harding, B. N., Santi, M., Holland‐Bouley, K. D., Clancy, R. R., Porter, B. E., Heuer, G. G., & Marsh, E. D. (2015) · Journal of Neurosurgery Pediatrics · doi:10.3171/2015.5.peds14551 · Cited by 53
Dravet syndrome: Early electroclinical findings and long‐term outcome in adolescents and adults
Darra, F., Battaglia, D., Dravet, C., Patrini, M., Offredi, F., Chieffo, D. R. P., Piazza, E., Fontana, E., Olivieri, G., Turrini, I., et al. (2019) · Epilepsia · doi:10.1111/epi.16297 · Cited by 59
“In our two cohorts, in line with previous reports, 5 ‒ 9, 11, 13, 19, 21 in the A second aim of our study was to clarify which early characteristics of the disease may predict the outcome of DS in adolescence and adulthood.”
ResultAuvin, S., Damera, V., Martin, M., Holland, R., Simontacchi, K. C., & Saich, A. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108239 · Cited by 53
Harnessing the Power of Metabolism for Seizure Prevention: Focus on Dietary Treatments
Hartman, A. L., & Stafstrom, C. (2012) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.09.019 · Cited by 52
“Clinically, Dravet syndrome typically begins with a prolonged febrile seizure in the first year of life, followed later in childhood by medically intractable seizures, developmental delays, and movement disorders including myoclonus, with further neurological deterioration into adulthood [26].”
BackgroundSchuster, J., Laan, L., Klar, J., Jin, Z., Huss, M., Korol, S. V., Hikmet, F., Sobol, M., Birnir, B., & Dahl, N. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104583 · Cited by 52
Aljaafari, D., Fasano, A. A., Nascimento, F. A., Lang, A. E., & Andrade, D. M. (2017) · Epilepsia · doi:10.1111/epi.13692 · Cited by 53
Kalser, J., & Cross, J. H. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000535 · Cited by 56
“Even in adulthood, an improvement in cognitive performance might be seen after achieving better seizure control, as observed in two adult patients with Dravet syndrome by Catarino et al [29].”
BackgroundSelf-citationTreatment issues for children with epilepsy transitioning to adult care
Nabbout, R., Camfield, C., Andrade, D. M., Arzimanoglou, A. A., Chiron, C., Cramer, J. A., French, J. A., Kossoff, E. H., Mula, M., & CAMFIELD, P. R. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.008 · Cited by 52
Barco, T. L., Kuchenbuch, M., Garcelon, N., Neuraz, A., & Nabbout, R. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01936-9 · Cited by 48
Audit of use of stiripentol in adults with Dravet syndrome
Balestrini, S., & Sisodiya, S. M. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12611 · Cited by 48
Self-citationJuandó‐Prats, C., James, E. S., Bilder, D. A., McNair, L. A., Kenneally, N., Helfer, J., Huang, N., Vila, M. C., Sullivan, J. E., Wirrell, E. C., et al. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108198 · Cited by 44
NaV1.1 haploinsufficiency impairs glutamatergic and GABAergic neuron function in the thalamus
Studtmann, C., Ladislav, M., Topolski, M. A., Safari, M., & Swanger, S. A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105672 · Cited by 40
Voltage‐gated sodium channels in genetic epilepsy: up and down of excitability
Rusina, E., Simonti, M., Duprat, F., Cestèle, S., & Mantegazza, M. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15947 · Cited by 39
Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain
Auvin, S., Lecointe, C., Dupuis, N., Desnous, B., Lebon, S., Gressèns, P., & Dournaud, P. (2013) · Epilepsia · doi:10.1111/epi.12401 · Cited by 38
“Two randomized trials demonstrated the efficacy of STP in combination with clobazam (CLB) and valproate (VPA) in children with Dravet syndrome (Chiron et al., 2000).”
BackgroundSCN1A variants associated with sudden infant death syndrome
Brownstein, C. A., Goldstein, R. D., Thompson, C. H., Haynes, R. L., Giles, E. K., Sheidley, B. R., Bainbridge, M., Haas, E. A., Mena, O. J., Lucas, J. R., et al. (2018) · Epilepsia · doi:10.1111/epi.14055 · Cited by 37
“The limited literature on neuropathological abnormalities in patients with SCN1A-related epilepsy includes hippocampal sclerosis, focal cortical dysplasia, periventricular heterotopia, micronodular dysplasia of the medial temporal lobe, and granule cell dispersion of the dentate gyrus.(23) Dentate bilamination, as see…”
BackgroundEpilepsy in Dravet Syndrome—Current and Future Therapeutic Opportunities
Gao, C., Pielas, M., Jiao, F., Mei, D., Wang, X., Kotulska, K., & Jóźwiak, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072532 · Cited by 37
Pescosolido, M. F., Uzun, E. D. G., Nagpal, S., & Morrow, E. M. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.01.003 · Cited by 42
Focal epilepsy in SCN1A ‐mutation carrying patients: is there a role for epilepsy surgery?
Vezyroglou, A., Varadkar, S., Bast, T., Hirsch, É., Strobl, K., Harvey, A. S., Epilepsy Surgery in SCN1A Study Group, Scheffer, I. E., Sisodiya, S. M., & Cross, J. H. (2020) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14588 · Cited by 36
Self-citationInvestigation of hypoxia‐inducible factor‐1α in hippocampal sclerosis: A postmortem study
Feast, A. R., Martinian, L., Liu, J. Y. W., Catarino, C. B., Thom, M., & Sisodiya, S. M. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03591.x · Cited by 38
“Conversely, PM studies also highlight that HS is not always present despite years of frequent seizures (Thom et al., 2005; Catarino et al., 2011).”
BackgroundSelf-citationSocial cognition and psychopathology in childhood and adolescence
Besag, F., & Vasey, M. J. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.03.015 · Cited by 38
Dysarthria and broader motor speech deficits in Dravet syndrome
Turner, S. J., Brown, A., Arpone, M., Anderson, V., Morgan, A. T., & Scheffer, I. E. (2017) · Neurology · doi:10.1212/wnl.0000000000003635 · Cited by 33
Self-citationFry, A. E., Rees, E., Thompson, R., Mantripragada, K. K., Blake, P., Jones, G., Morgan, S., Jose, S., Mugalaasi, H., Archer, H. L., et al. (2016) · BMC Medical Genetics · doi:10.1186/s12881-016-0294-2 · Cited by 35
“Furthermore, in contrast to paediatric settings, the significance of SCN1A mutations for adult patients is often neglected [66], usually because key elements of early history (e.”
ResultSeizing control of epileptic activity can improve outcome
Chapman, K. E., Specchio, N., Shinnar, S., & Holmes, G. L. (2015) · Epilepsia · doi:10.1111/epi.13109 · Cited by 32
Cognitive and Social Outcomes of Epileptic Encephalopathies
Nickels, K. C., & Wirrell, E. C. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.10.001 · Cited by 37
Patodia, S., Tachrount, M., Somani, A., Scheffer, I. E., Yousry, T. A., Golay, X., Sisodiya, S. M., & Thom, M. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12638 · Cited by 32
Self-citationExome sequencing for patients with developmental and epileptic encephalopathies in clinical practice
Scheffer, I. E., Bennett, C. A., Gill, D., de Silva, M. G., Boggs, K., Marum, J., Baker, N., Flagship, A. G. D., Palmer, E. E., & Howell, K. B. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15308 · Cited by 31
Self-citationTranslating Cerebellar Purkinje Neuron Physiology To Progress In Dominantly Inherited Ataxia
Chopra, R., & Shakkottai, V. G. (2014) · Future Neurology · doi:10.2217/fnl.14.6 · Cited by 32
Puka, K., Tavares, T. P., & Speechley, K. N. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.01.012 · Cited by 30
Electroencephalographic features of patients with SCN1A-positive Dravet syndrome
Lee, H.-F., Chi, C., Tsai, C., Chen, C.-H., & Wang, C. (2014) · Brain and Development · doi:10.1016/j.braindev.2014.10.003 · Cited by 28
Stiripentol for the treatment of seizures associated with Dravet syndrome
Chiron, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1593142 · Cited by 29
“Seizure frequency may occasionally still be reduced and performances still be improved despite a long history of refractory epilepsy [34,46,47,53,54], but only a small proportion (3/13) of patients were responders in a small DS series with STP initiated at a mean age of 26 years [55].”
BackgroundSeizures and Epilepsy in Autism Spectrum Disorder
Besag, F., & Vasey, M. J. (2020) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.02.002 · Cited by 28
The impact of SARS-CoV-2 vaccination in Dravet syndrome: A UK survey
Clayton, L. M. S., Balestrini, S., Cross, J. H., Wilson, G., Eldred, C., Evans, H. S., Koepp, M. J., & Sisodiya, S. M. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108258 · Cited by 26
“Fever sensitivity, as a trigger for seizures, persists into adult life in many individuals with DS [3].”
BackgroundSelf-citationOutlining a core neuropsychological phenotype for Dravet syndrome
Battaglia, D., Ricci, D., Chieffo, D. P. R., & Guzzetta, F. (2015) · Epilepsy Research · doi:10.1016/j.eplepsyres.2015.11.020 · Cited by 28
Seizures and Epilepsy in Autism Spectrum Disorder
Besag, F., & Vasey, M. J. (2021) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.11.005 · Cited by 28
Hamelin, S., & Depaulis, A. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.01.560 · Cited by 23
Dravet syndrome: From neurodevelopmental to neurodegenerative disease?
Selvarajah, A., Sabo, A., Gorodetsky, C., Marques, P., Chandran, I., Thompson, M. D., Ali, Q. Z., McAndrews, M. P., Tartaglia, M. C., Lira, V. S. T., et al. (2025) · Epilepsia · doi:10.1111/epi.18329 · Cited by 23
“19,29 In clinical practice, caregivers of adults with DS often complain about loss of previously acquired skills, especially as patients age.”
Genetics of Epilepsy and Relevance to Current Practice
Michelucci, R., Pasini, E., Riguzzi, P., Volpi, L., Dazzo, E., & Nobile, C. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0281-8 · Cited by 23
Evaluation of Presumably Disease Causing SCN1A Variants in a Cohort of Common Epilepsy Syndromes
Lal, D., Reinthaler, E. M., Dejanovic, B., May, P., Thiele, H., Lehesjoki, A., Schwarz, G., Riesch, E., Ikram, M. A., van Duijn, C. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150426 · Cited by 23
A registry for Dravet syndrome: The Italian experience
Balestrini, S., Doccini, V., Giometto, S., Lucenteforte, E., De Masi, S., Giarola, E., Brambilla, I., Pieroni, F., Perulli, M., Battaglia, D., et al. (2023) · Epilepsia Open · doi:10.1002/epi4.12730 · Cited by 21
Metadata
- Authors
- Catarino, C. B., Liu, J. Y. W., Liagkouras, I., Gibbons, V. S., Labrum, R. W., Ellis, R., Woodward, C., Davis, M. B., Smith, S. J., Cross, J. H., Appleton, R. E., Yendle, S. C., McMahon, J. M., Bellows, S. T., Jacques, T. S., Zuberi, S. M., Koepp, M. J., Martinian, L., Scheffer, I. E., Thom, M., & Sisodiya, S. M.
- Affiliations
- National Hospital for Neurology and Neurosurgery (GB)
- Royal Hospital for Children (GB)
- Great Ormond Street Hospital (GB)
- Alder Hey Children's NHS Foundation Trust (GB)
- The University of Melbourne (AU)
- Royal Children's Hospital (AU)
- Corresponding author
- Sisodiya, S. M.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-29
- Volume
- 134
- Issue
- 10
- Pages
- 2982-3010
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3187538
- OpenAlex
- W2147751393
- Cited by
- 227
- References
- 88
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 13 · 2023: 11 · 2022: 15 · 2021: 21 · 2020: 16 · 2019: 13 · 2018: 12 · 2017: 13 · 2016: 17 · 2015: 12 · 2014: 19 · 2013: 19 · 2012: 14
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- WestminsterResearch (University of Westminster) (submittedVersion, cc-by-nc)
- Funders
- Wellcome Trust (084730)
- National Institute for Health and Care Research
- Great Ormond Street Hospital Charity
- University College London Hospitals NHS Foundation Trust
- Medical Research Council
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- Dravet syndrome, epileptic encephalopathy, SCN1A mutations, adult-onset epilepsy, long-term clinical course, neuropathology, dysphagia, cognitive decline, drug-resistant epilepsy, seizure semiology, postmortem brain
- MeSH terms
- Adult, Aged, Brain, Cognition Disorders, Epilepsies, Myoclonic, Female, Humans, Male, Middle Aged, Mutation, Nerve Tissue Proteins, Syndrome, Sodium Channels, Disease Progression, NAV1.1 Voltage-Gated Sodium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.